Mycosis fungoides is the most common cutaneous lymphoma in the US, and it is increasing rapidly in both incidence and mortality. Our knowledge of its prognosis derives primarily from case series, which are subject to possible selection bias and other limitations. The current analysis examines trends in survival and prognostic factors in data from nine population-based cancer registries in the US. Among the 650 cases followed with known dates of diagnosis and no history of prior malignancy, the median survival time was 7.8 years. Advanced age, black race, prior malignancy, and Sezary syndrome presence at the time of diagnosis were each independently associated with poor prognosis. Fatality was not influenced by sex or geographic area. There was no consistent evidence of improved survival with time over the 12-year study period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1097-0142(19881015)62:8<1658::aid-cncr2820620834>3.0.co;2-j | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The notch sign as a clue for the diagnosis of early cutaneous T-cell lymphoma.
JAAD Case Rep
February 2025
Department of Dermatology, Cliniques universitaires Saint-Luc UCLouvain, Brussels, Belgium.
Hypopigmented mycosis fungoides: an important differential diagnosis of hypochromias in childhood.
Rev Paul Pediatr
January 2025
Universidade do Estado do Pará, Belém, PA, Brazil.
Objective: To highlight the importance of early recognition of hypopigmented mycosis fungoides (HMF) in cases of cutaneous hypochromia in children, with a view to an effective diagnostic and therapeutic approach.
Case Description: Two cases of HMF in children are reported. The first case involves an eight-year-old boy with hypochromic macules on the trunk and root of the upper and lower limbs, while the second case is a six-year-old boy with widespread hypochromic patches.
Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.
J Dtsch Dermatol Ges
January 2025
Department of Dermatology, Venereology and Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Background And Objectives: Patients with cutaneous lymphomas (CL) are at an increased risk of developing secondary malignancies. This study aimed to assess the frequency of association between CL and Kaposi sarcoma (KS) and to identify factors that may promote the co-occurrence of these two diseases.
Patients And Methods: On January 25, 2024, we conducted a systematic search of four electronic medical databases to identify all published cases of KS associated with CL.
Ultra-high-frequency Ultrasound in the Objective Assessment of Chlormethine Gel Efficacy: A Case Report.
Acta Dermatovenerol Croat
November 2024
Agata Janowska, MD, Department of Dermatology, , University of Pisa, Via Roma 67, 56126, Pisa, Italy; Phone: +39 050 992436, Fax: +39 050 992556,
Mycosis fungoides (MF) represent the most frequent form of cutaneous T-cell lymphoma (CTCL). Chlormethine gel has been approved as first-line therapy in MF. The classification of early forms of MF is clinically and histologically complex even for experienced clinicians.
View Article and Find Full Text PDFAdvances in Novel Systemic Therapies for the Management of Cutaneous T Cell Lymphoma (CTCL).
Curr Hematol Malig Rep
January 2025
Department of Hematology, Winship Cancer Institute, Atlanta, GA, USA.
Article Synopsis
- Cutaneous T cell lymphomas (CTCLs) are challenging to treat non-Hodgkin lymphomas, with Mycosis fungoides (MF) and Sezary syndrome (SS) being the most prevalent subtypes.
- There is no established standard treatment or cure for these conditions, making management difficult.
- Recent clinical trials are testing new therapies, including innovative chemotherapies, antibodies, immunotherapies, and cellular therapies that could enhance treatment options for MF and SS.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!